Bonus Biogroup Ltd. filed a Form F-1 registration statement for an initial public offering on 2025-05-09. It has amended it 4 times. As of its latest filing, on 2026-03-31, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have applied to list the ADSs on the Nasdaq Capital Market, or Nasdaq, under the symbol “BONS.” This offering is contingent upon the listing of the ADSs on Nasdaq.From the F-1/A filed 2026-03-31
Shares offered
We are offering 3,750,000 American Depositary Shares, or ADSs, through the underwriter named in this prospectus.From the F-1/A filed 2026-03-31
Price range
The estimated initial public offering price is between $4.00 and $6.00 per ADS.From the F-1/A filed 2026-03-31
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash resources, as follows:From the F-1/A filed 2026-03-31
Net loss or income
Since the date of the Private Placement Agreement, and as of December 31, 2025, we have incurred net losses of NIS 362.1 million (equivalent to approximately $113.5 million).From the F-1/A filed 2026-03-31
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-05-09 | Registration statement filed (foreign issuer) | F-1 |
| 2025-11-28 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-12 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-19 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-31 | Registration statement amended (foreign issuer) | F-1/A |
Tools for this story
Each opens in a new tab, filled in for Bonus Biogroup Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.